General Announcement::GPL secures marketing authorization in Germany for Seretide Accuhaler

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
10-Sep-2018 11:30:35
Status
New
Announcement Sub Title
GPL secures marketing authorization in Germany for Seretide Accuhaler
Announcement Reference
SG180910OTHRRUV6
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
10/09/2018 17:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark secures marketing authorization in Germany for its generic version of Seretide Accuhaler

Attachments

PR_10092018.pdf
Total size =3296K